Asian Journal Of Social Pharmacy

Abstract: Objective To provide theoretical basis for clinical treatment of patients with terminal non-small cell lung cancer through the analysis of the cost and adverse reactions of the joint treatment of icotinib and pemetrexed combined with cisplatin. Methods The clinical data of the patients diagnosed with terminal non-small cell lung cancer were collected and analyzed according to different drug administration schedules (n = 53 of each group). The efficacy, cost and adverse reactions were evaluated respectively, aiming to provide the pharmacoeconomic evidence for the clinical applications. Results and Conclusion There was no significant difference between the efficacy of the icotinib group and the pemetrexed combined with cisplatin group, but the cost of the icotinib group was much lower, and the adverse reactions such as leukopenia, anemia, vomiting and nausea were far fewer than those in the pemetrexed combined cisplatin group. Although the two methods have similar therapeutic effects, the icotinib group has lower cost and fewer adverse reactions. Thus, from the perspective of pharmacoeconomics, icotinib has its advantage over the traditional regimen on the treatment of terminal non-small cell lung cancer.

Key words: non-small cell lung cancer (NSCLC), icotinib, pemetrexed, cisplatin